Literature DB >> 24118279

Cervical pregnancy: a report of four cases.

Keiko Kochi1, Takao Hidaka, Kuniaki Yasoshima, Kenji Yoneda, Kazunori Arai, Takashi Arai.   

Abstract

Various conservative treatments for cervical pregnancy have been reported. However, unlike tubal ectopic pregnancy, the treatment of cervical pregnancy has not been well established. For patients who desire fertility preservation, treatment with methotrexate chemotherapy carries a high success rate for preservation of the uterus. When methotrexate is injected i.v. or i.m., expulsion of pregnant tissue occasionally takes up to 1 month. In this report, we present four cases of cervical pregnancy which were successfully managed by methotrexate injection into the bilateral uterine arteries. In cases presenting with massive bleeding, embolization of the bilateral uterine arteries was performed. Cervical pregnancy was aborted within 8 days safely, and fertility could be preserved without harmful side-effects.
© 2013 The Authors. Journal of Obstetrics and Gynaecology Research © 2013 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  cervical pregnancy; chemotherapy; ectopic pregnancy; intra-arterial injection; methotrexate

Mesh:

Substances:

Year:  2013        PMID: 24118279     DOI: 10.1111/jog.12185

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  2 in total

1.  Conservative management of cervical pregnancy with intramuscular administration of methotrexate and KCl injection: Case report and review of the literature.

Authors:  Stamatios Petousis; Chrysoula Margioula-Siarkou; Ioannis Kalogiannidis; George Karavas; Vasileios Palapelas; Nikolaos Prapas; David Rousso
Journal:  World J Clin Cases       Date:  2015-01-16       Impact factor: 1.337

2.  Ectopic Cervical Pregnancy: Treatment Route.

Authors:  Guglielmo Stabile; Francesco Paolo Mangino; Federico Romano; Giulia Zinicola; Giuseppe Ricci
Journal:  Medicina (Kaunas)       Date:  2020-06-12       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.